دورية أكاديمية
Preclinical support for tumor protein D52 as a cancer vaccine antigen
العنوان: | Preclinical support for tumor protein D52 as a cancer vaccine antigen |
---|---|
المؤلفون: | Robert K. Bright |
المصدر: | Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023) |
بيانات النشر: | Taylor & Francis Group, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology |
مصطلحات موضوعية: | TPD52 (D52), mD52 (murine orthologue TPD52), hD52 (human orthologue TPD52), overexpressed tumor-self antigen, oncogenic, shared, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950 |
الوصف: | ABSTRACTOverexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over expressed TAA actively involved in transformation, leading to increased proliferation and metastasis. TPD52 overexpression has been demonstrated in many human adult and pediatric malignancies. The murine orthologue of TPD52 (mD52) parallels normal tissue expression patterns and known functions of human TPD52 (hD52). Here in we present our preclinical studies over the past 15 years which have demonstrated that vaccine induced immunity against mD52 is effective against multiple cancers in murine models, without inducing autoimmunity against healthy tissues and cells. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 21645515 2164-554X 2164-5515 |
Relation: | https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X |
DOI: | 10.1080/21645515.2023.2273699 |
URL الوصول: | https://doaj.org/article/e3ae3616fe0541bb9eaa1bdea471b023 |
رقم الأكسشن: | edsdoj.3ae3616fe0541bb9eaa1bdea471b023 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 21645515 2164554X |
---|---|
DOI: | 10.1080/21645515.2023.2273699 |